JPS5913766A - 新規の１−フエニル−２，４−ベンゾジアゼピン誘導体及びその製法 - Google Patents
新規の１−フエニル−２，４−ベンゾジアゼピン誘導体及びその製法Info
- Publication number
- JPS5913766A JPS5913766A JP12223382A JP12223382A JPS5913766A JP S5913766 A JPS5913766 A JP S5913766A JP 12223382 A JP12223382 A JP 12223382A JP 12223382 A JP12223382 A JP 12223382A JP S5913766 A JPS5913766 A JP S5913766A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- formula
- methyl
- tetrahydro
- benzodiazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WNHDGNNXQWBJAP-UHFFFAOYSA-N 1-phenyl-2h-2,4-benzodiazepine Chemical class C=12C=CC=CC2=CNC=NC=1C1=CC=CC=C1 WNHDGNNXQWBJAP-UHFFFAOYSA-N 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 230000003533 narcotic effect Effects 0.000 abstract description 4
- 125000005843 halogen group Chemical group 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- OXHPTABOQVHKLN-UHFFFAOYSA-N 1-(2-bromoethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCBr)C=C1 OXHPTABOQVHKLN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LKTRGYCDCTYFTM-UHFFFAOYSA-N 2,4-benzodiazepin-1-one Chemical compound O=C1N=CN=CC2=CC=CC=C12 LKTRGYCDCTYFTM-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108700018454 CDC15 Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 101100029577 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDC43 gene Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102220411551 c.74G>T Human genes 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 101150081467 cdc15 gene Proteins 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12223382A JPS5913766A (ja) | 1982-07-15 | 1982-07-15 | 新規の１−フエニル−２，４−ベンゾジアゼピン誘導体及びその製法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12223382A JPS5913766A (ja) | 1982-07-15 | 1982-07-15 | 新規の１−フエニル−２，４−ベンゾジアゼピン誘導体及びその製法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5913766A true JPS5913766A (ja) | 1984-01-24 |
| JPH0357896B2 JPH0357896B2 (enrdf_load_stackoverflow) | 1991-09-03 |
Family
ID=14830862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12223382A Granted JPS5913766A (ja) | 1982-07-15 | 1982-07-15 | 新規の１−フエニル−２，４−ベンゾジアゼピン誘導体及びその製法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5913766A (enrdf_load_stackoverflow) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04118295U (ja) * | 1991-03-29 | 1992-10-22 | 日本橋梁株式会社 | 圧縮・破砕装置 |
| JPH0528589U (ja) * | 1991-09-17 | 1993-04-16 | 株式会社岩内 | 空缶の圧潰処理装置 |
| US5380721A (en) * | 1990-09-10 | 1995-01-10 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
| EP1346990A1 (en) * | 2002-03-06 | 2003-09-24 | National Institute of Advanced Industrial Science and Technology | Catalyst for synthesizing alkylene carbonates |
-
1982
- 1982-07-15 JP JP12223382A patent/JPS5913766A/ja active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380721A (en) * | 1990-09-10 | 1995-01-10 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
| US5624922A (en) * | 1990-09-10 | 1997-04-29 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
| JPH04118295U (ja) * | 1991-03-29 | 1992-10-22 | 日本橋梁株式会社 | 圧縮・破砕装置 |
| JPH0528589U (ja) * | 1991-09-17 | 1993-04-16 | 株式会社岩内 | 空缶の圧潰処理装置 |
| EP1346990A1 (en) * | 2002-03-06 | 2003-09-24 | National Institute of Advanced Industrial Science and Technology | Catalyst for synthesizing alkylene carbonates |
| US6933394B2 (en) | 2002-03-06 | 2005-08-23 | National Institute Of Advanced Industrial Science And Technology | Catalyst for synthesizing alkylene carbonate |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0357896B2 (enrdf_load_stackoverflow) | 1991-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69201058T2 (de) | Perhydroisoindol derivate und ihre herstellung. | |
| US5536832A (en) | N-acyl-2,3-benzodiazepine derivatives pharmaceutical compositions containing them and process for preparing same | |
| DE69220258T2 (de) | Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung | |
| US7544708B2 (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
| IE47200B1 (en) | Isoxazolo (5,4-c)pyridine derivatives,their preparation and pharmaceutical compositions containing them | |
| DE68905365T2 (de) | Benzodiazepine, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre therapeutische Verwendung. | |
| DE3650567T2 (de) | Medizinische Indol- und Indazol-Ketosulfonderivate | |
| Baumgarten et al. | Cinnolines. VI. The Structure of Neber's Lactam. A New Synthesis of 3-Cinnolinol1, 2 | |
| DE69621877T2 (de) | 4-Indolylpiperazinyl-Derivate | |
| CH643554A5 (de) | Verfahren zur herstellung von piperidinopropanolderivaten. | |
| DE68918257T2 (de) | 4,5,6,7-Tetrahydrobenzimidazol-Derivate und ihre Herstellung. | |
| JPS5913766A (ja) | 新規の１−フエニル−２，４−ベンゾジアゼピン誘導体及びその製法 | |
| CH643268A5 (de) | Pyrrolo- oder pyrido(2,1-c)(1,4)thiazine oder -thiazepine. | |
| DE69113505T2 (de) | Spiro-Derivate von Dibenzosuberan. | |
| JPH045289A (ja) | アミド化合物 | |
| EP0389425B1 (de) | Neue Benzothiopyranylamine | |
| KR20150066777A (ko) | 광학활성 인돌린 유도체 및 이의 제조방법 | |
| DE69029198T2 (de) | Cholecystokinin-antagonisten | |
| DE68906647T2 (de) | Hydroxy-1,2,3,4-tetrahydroaminoacridine, Verfahren für ihre Herstellung und ihre Verwendung als Arzneimittel. | |
| CH628885A5 (en) | Piperidine derivative | |
| Taborsky et al. | Synthesis and preliminary pharmacology of some 1-methylindoles | |
| IL42007A (en) | 2 - Benzoyl - 3 - Amino - Pyridines | |
| DE2603417A1 (de) | 4-substituierte amino-alpha-aminomethylbenzylalkoholderivate | |
| DE69532641T2 (de) | Verfahren und zwischenprodukte zur herstellung von 5,7-dihydro-3-(2 1-benzylpiperidin-4-yl ethyl)-6h-pyrrolo-(4,5-f)-1,2-benzisoxazol-6-on | |
| DE2921978A1 (de) | 3-amino-2-(5-fluoro- und 5-methoxy-1 h-indol-3-yl)-propansaeurederivate und arzneimittel, welche diese enthalten und verfahren zur herstellung der neuen verbindungen |